The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
Cell, gene, and other novel therapies require carefully designed and well executed logistics solutions for supplying lifesaving medicine to patients. Biological material sourced and produced for autologous and allogeneic therapies must be strictly controlled for temperature, timeline, as well as chain of identity and custody. This complexity was expanded by the COVID pandemic which has caused disruption in supply of materials, as well as manufacturing and logistics processes. On the other hand, smart technologies, digital solutions, and innovative operation models have driven the rapid evolution of global CGT clinical and commercial distribution. This session will explore the following topics: • Planning and ensuring manufacturing capacity to serve the patient/market need. • Solving supply chain challenges for clinical and/or commercial cell therapy products. • Case studies of digital solution (electronic system integration), smart technologies and operation model successfully applied in supply chain management.
The Cell Therapies products space is continuing to build on the potential for innovative treatments for unmet patient needs. Topics include cell products with unique manufacturing process, complex sourcing starting material, and assays with direct relevance to CQAs…
In recent years, cell and gene therapies have evolved rapidly into approved products for the treatment of both incurable genetic diseases as well as for the treatment of certain cancers…